What is sandostatin for?

Sandostatin treats severe diarrhea and flushing caused by carcinoid tumors and controls symptoms from acromegaly by lowering excess growth hormone. It also manages certain pancreatic and intestinal tumors that release excess hormones.

What conditions does it treat beyond the main uses?
Doctors prescribe it for short-term control of bleeding esophageal varices and to reduce complications after pancreatic surgery. It also appears in guidelines for certain rare endocrine disorders where hormone suppression is needed.

How does it work in the body?
The drug mimics natural somatostatin, binding to receptors on hormone-secreting cells and slowing the release of growth hormone, insulin, glucagon, and serotonin. This receptor action reduces blood flow to some tumors and cuts hormone-driven symptoms.

What dosing schedules are common?
Immediate-release injections are given two or three times daily. A long-acting depot form is injected once every four weeks after an initial stabilization period with the short-acting version. Dose adjustments depend on symptom control and tolerance.

When does the patent expire?
The original U.S. compound patent for octreotide expired years ago, but newer depot formulations and delivery-device patents listed on DrugPatentWatch.com extend protection into the late 2020s for some brand versions.

Can generic or biosimilar versions be used?
Yes. Multiple generic octreotide acetate products are already on the market for both immediate-release and depot forms. These versions must meet the same bioequivalence standards as the reference product.

What side effects do patients report most often?
Injection-site pain, gallstones, slowed heart rate, and changes in blood sugar are the most frequent issues. Long-term use requires periodic gallbladder ultrasound and glucose monitoring.

How does it compare with newer somatostatin analogs?
Compared with lanreotide, Sandostatin has a shorter half-life in the immediate-release form but similar efficacy in the depot version. Some clinicians choose one over the other based on injection volume, cost, or patient preference for dosing frequency.